Small Cell Lung Cancer Spotlight - Episode 6
Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.
One of the big stories in oncology in 2021 has been the tale of “dangling approvals.” These are accelerated approvals that landed in limbo, after follow-up trials failed to confirm the results that prompted the FDA to allow these cancer drugs to reach the market for certain patients.
The FDA held 3 days of hearings in late April to weigh whether some therapies in this category should stay on the market with their current indications.1,2 However, in some cases, manufacturers voluntarily withdrew indications after talks with the agency. During the hearings, some manufacturers cited the fact that their therapies were already incorporated into the National Comprehensive Cancer Network (NCCN) Clinical Guidelines, and thus in use.
Two such cases involved the PD-1 inhibitors nivolumab (Opdivo), from Bristol Myers Squibb, and pembrolizumab (Keytruda), from Merck. Indications were withdrawn for some patients with metastatic small cell lung cancer (SCLC),3,4 a cancer type in which some progress in treatment advances has been made of late, but in which there is still great unmet need.
The question is, what now? For a discussion on how leading clinicians are responding to these announcements, along with other developments in SCLC, The American Journal of Managed
Care® (AJMC®) spoke with Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for translational research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania.
This interview has been edited lighted for clarity.
AJMC®: Over the past year, we’ve seen the voluntary withdrawal of some indications in SCLC after the FDA moved to address what it calls “dangling approvals.” What are your thoughts on how this process played out?
EDELMAN: The most important thing to understand is, it’s not that the drugs were not effective. It was that the trial design, [or] probably the nature of the population, had changed. With these immunotherapy drugs, since the initial approvals, similar agents have now been demonstrated to be effective in combination with chemotherapy in the front line. So, the use of them in second and subsequent lines of therapy became more questionable. But it’s not that they were not effective.
The FDA processes continue to evolve over time. They’re not always as clear as we’d like—what’s the basis for approval? In the past, it had to be based upon a fairly hard point of overall survival;
then they moved to other issues in terms of progression-free survival and sometimes response rate. So, it’s not always obvious as to why something is approved.
But I think in this situation, it’s important to recognize that pembrolizumab and nivolumab in second line for SCLC are, in fact, drugs that do potentially have utility in populations who have
not received immunotherapy alone or in combination previously.
I think part of the basis for removing the approval was that, in the future, [the FDA] didn’t want patients who had gotten immunotherapy as part of their initial treatment with one drug to get essentially another anti–PD-1 or anti–PD-L1 in second- or third-line therapy. That’s reasonable, but a number of patients still will not have received immunotherapy as part of their initial treatment; for them, an immunotherapy agent is still reasonable down the road.
AJMC®: How do the recent FDA proceedings affect the NCCN guideline process, specifically in SCLC?
EDELMAN: Because I’m actually on that committee, I don’t know to what extent I can discuss deliberations. But an NCCN guideline will still list these as potential agents, in second- or third-line use. I think that, as I said, there’s no question that these are active agents. [As for] the NCCN process…certainly the FDA approvals and disapprovals can influence that. But again, it doesn’t take away from the potential guideline, which moves down from being heavily based on evidence in randomized phase 3 studies, to more expert opinion—but certainly a fair amount of published evidence, prospective studies, indicating activity in these drugs.
AJMC®: What kinds of questions do physicians and even patients have about immunotherapy and SCLC relative to other types of treatment?
EDELMAN: Immunotherapy certainly gets a lot of buzz. I can’t think of other [therapies] that have TV commercials. In lung cancer, I kind of knew we had hit the big time when suddenly, there were
TV commercials for immunotherapeutics. I was watching one of these, and I said to my wife, “You know, it’s no day at the beach.” And the next thing is they show this guy walking on the beach.
They are drugs that have a role in the treatment of cancer—they are not the only drugs. Patients should understand that these can be potentially valuable agents—in some instances, indispensable
agents—but they are part of a larger strategy, which may include chemotherapy, radiation, sometimes even surgery. They are drugs that certainly have potentially significant and even lethal adverse effects [AEs]. For the most part, [they] lack the acute AEs that we are used to seeing with chemotherapy—[however], even those [effects] to a large extent are ameliorated with modern antinausea therapies, etc.
You don’t have that potential for nausea, hair loss, etc, that you still see with chemotherapy, but the AEs of immunotherapy can be quite profound. They are less predictable. I spend a lot of time educating patients about AEs of all therapies: chemotherapy, immunotherapy, radiotherapy, etc, and their combinations. But immunotherapy is no day at the beach. Many patients feel very well until they don’t. Some go through their course of treatment and have remarkably few AEs. Other people can get life-threatening effects. Sometimes, interestingly, those may presage really dramatic and long-term benefit. But people can get life-altering therapy [and have] problems, [such as] diabetes, which requires lifelong insulin. It’s a very unpredictable set of AEs. They are drugs that require a great deal of respect.
AJMC®: After a stretch of time in which comparatively less progress was made in treating SCLC than non–small cell lung cancer (NSCLC), SCLC has seen the recent designation of subtypes.5 How do you expect this advance to affect patient care?
EDELMAN: A number of subtypes have been described, primarily based upon cell lines and
archive tissues. We do not yet have any prospective clinical data on the utility of these types. So, that remains to be seen. If I sound a little cynical about that, it’s because after 30 years or so of work in the field, a lot of stuff that comes from biology doesn’t always translate. On the other hand, if you don’t have the biology, you’ll never get there. So, some of these subtypes, I think, may help to better identify who will respond to immunotherapy. Clearly, that’s one of the subtypes. And, it would be good if we knew—it’s important to know—in whom things will work as well as in whom things will not work.
Because if you give somebody immunotherapy and it doesn’t work, then that’s both expensive and
potentially dangerous. It’s never good to get AEs with no chance of benefit. So that’s one aspect that I think will be really important. The other side is to figure out who will benefit from chemotherapy, and from which chemotherapy drugs. There does appear to be some evidence that may be useful, but we need to have well-designed, good clinical trials that tell us, “This is better.” I look forward to those studies.
AJMC®: How will the rise of advances in the use of biomarkers aff ect treatment of SCLC going forward?
EDELMAN: The biomarkers are the clinical subtypes—and to extent that some of those are
already available in SCLC, you will need, number 1, to have an adequate tissue size. So, I think something that will change is that there will be demand for more tissue.
We saw this in NSCLC. Years ago, I ran a prospective study in what was then the Cancer
and Leukemia Group B.6 This was NSCLC, and we needed tissue, and people kind of screamed and
yelled and said, “There’s just no way we can get tissue and analyze it before we treat people for
cancer.” That was unimaginable. And it wasn’t so very long ago—it was about 2006. That problem
delayed that study for a couple of years and may have contributed to it failing, because the marker
that we had identified was in immunohistochemistry.
There are antibodies, they shift, [and] so we never could cross-validate back to the original specimens. But the fact is, that [this work] will require that we get bigger chunks of tissue. Hopefully it will turn out like NSCLC, where it will just become routine. We’ll be able to say, I’ve got a higher probability that this [vs that] will be beneficial.
The issue of SCLC is going to be more complex than NSCLC. In NSCLC, where we have biomarkers
like EGFR, ALK, ROS1, or RET, the treatments that we have are extremely effective—basically, they’re
80% to 90% eff ective, and they tend to be durable. The issue in SCLC has never been getting an initial response. The vast majority of patients respond to drugs that have been around for 30 to 40 years. The problem is maintaining the response. So, it will be the durability of response that’s far more crucial. And that’s where I mean no therapy has been remarkable.
Everybody always loves anecdotes. Here’s one: We had a patient who had progressed and was treated with definitive treatments, chemo and radiation, for a limited-stage SCLC. He relapsed, and he was placed on one of our trials that will be reported in a couple of weeks. Then he was on another study, on the control arm, [but in any case] that was another negative trial. And then he got a few doses of immunotherapy, anti–PD-L1 treatment, and ended up with a rip-roaring colitis after 3 or 4 doses. But he got better—his SCLC got better—from [the immunotherapy], more than 2 years ago, and I have not treated him for that since then. So, here’s a disease where the median life expectancy for recurrent refractory disease is measured in weeks—and yet it’s 2 years later. Actually, his big problems, currently, relate to his other smoking-related illnesses—his heart disease, his lung disease.
You wave a magic wand over a SCLC patient—take away their cancer—and they’re still stuck with their terrible heart and lung disease. That’s really a big rate-limiting step for a lot of this.
1. Beaver JA, Pazdur R. “Dangling” accelerated approvals in oncology. N Engl J Med. 2021;384(18):e68. doi:10.1056/NEJMp2104846
2. FDA in brief: FDA Oncologic Drugs Advisory Committee to review status of six indications granted accelerated approval. News release. FDA; March 11, 2021. Accessed May 8, 2021. https://www.fda.gov/newsevents/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committeereview-status-six-indications-granted-accelerated
3. Bristol Myers Squibb statement on Opdivo (nivolumab) small cell lung cancer US indication. Bristol Myers Squibb. News release; December 29, 2020. Accessed May 26, 2021. https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-
4. Merck provides update on Keytruda (pembrolizumab) indication in metastatic small cell lung cancer in the US. Merck. News release; March 1, 2021. Accessed May 26, 2021. https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-inmetastatic-small-cell-lung-cancer-in-the-us/
5. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346-360.e7. doi:10.1016/j.ccell.2020.12.014
6. Schilsky RL, McIntyre OR, Holland JF, Frei E. A concise history of the Cancer and Leukemia Group B. Clin Cancer Res. 2006;12(11Pt2):3553s-3555s.doi:10.1158/1078-0432.CCR-06-9000